Talazoparib

From WikiMD.org
Jump to navigation Jump to search

Talazoparib

Talazoparib (pronounced ta-LAZ-oh-par-ib) is a medication used in the treatment of certain types of breast cancer. It is a type of PARP inhibitor, which works by blocking the action of an enzyme called poly (ADP-ribose) polymerase (PARP) that is involved in DNA repair. By inhibiting PARP, talazoparib can cause cancer cells to die.

Etymology

The name "Talazoparib" is derived from the combination of letters from the words "TAlazopARIB". The prefix "Tal-" is an arbitrary designation, while "-azoparib" is a common suffix for PARP inhibitors.

Usage

Talazoparib is used to treat adults with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Patients must be selected for therapy based on an FDA-approved companion diagnostic for talazoparib.

Related Terms

  • PARP inhibitor: A type of drug that blocks the action of PARP and causes cancer cells to die.
  • BRCA mutation: A mutation in either of the BRCA1 and BRCA2 genes, which are tumor suppressor genes. Mutations in these genes can lead to the development of hereditary breast and ovarian cancer.
  • HER2-negative: A term used to describe a type of breast cancer that tests negative for a protein called human epidermal growth factor receptor 2 (HER2). HER2-negative breast cancers can be more difficult to treat than HER2-positive breast cancers.

Side Effects

Common side effects of talazoparib include fatigue, anemia, nausea, neutropenia, headache, thrombocytopenia, vomiting, alopecia, diarrhea, and decreased appetite.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski